532 results on '"Muss, H"'
Search Results
52. Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial.
53. Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907).
54. Adjuvant chemotherapy for older women with breast cancer
55. Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer
56. Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients
57. Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy
58. S36 Adjuvant treatment of elderly breast cancer patients
59. Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience
60. Patient preferences for adjuvant treatment of early-stage breast cancer
61. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG
62. Phase I/II feasibility trial of adjuvant dose-dense (DD) docetaxel/epirubicin/cyclophosphamide (TEC) in stage II/III breast cancer
63. S33 Special Issues Related to Adjuvant Therapy in ElderlyWomen
64. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
65. Cyclin D1 (CD1), interleukin-6 (IL-6), Ki67, transforming growth factor beta type II receptor, HER-2 and prediction of relapse in women with early stage breast cancer (BC) taking tamoxifen
66. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients
67. The role of HER-2 + Topo IIα amplification in predicting benefit from CAF dose escalation-CALGB 8541
68. Development of a comprehensive geriatric assessment (CGA) measure for older patients (Pts) with cancer: A feasibility study
69. A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome
70. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer
71. A randomized controlled trial of an educational program to improve accrual of older persons to cancer treatment protocols: CALGB 360001
72. Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen
73. Introduction: cancer in the elderly
74. Diagnosis and Treatment of Breast Cancer in the Elderly
75. Factors Used to Select Adjuvant Therapy of Breast Cancer in the United States: an Overview of Age, Race, and Socioeconomic Status
76. Role of adjuvant endocrine therapy in early-stage breast cancer
77. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.
78. Determinants of Black/White Differences in Colon Cancer Survival
79. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
80. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.
81. Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association
82. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
83. 5-Fluorouracil and Low-dose Leucovorin in the Treatment of Recurrent Epithelial Ovarian Carcinoma
84. 5-Fluorouracil and Low-dose Leucovorin in the Treatment of Recurrent Squamous Cell Carcinoma of the Cervix
85. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
86. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
87. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
88. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and...
89. Breast cancer in the elderly.
90. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association.
91. The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients
92. The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont.
93. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment].
94. Spinal cord compression in breast cancer.
95. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group).
96. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
97. High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast. A phase III study of the Piedmont Oncology Association (POA).
98. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion.
99. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association.
100. Nonseminomatous germ cell cancer of the testis. Reducing treatment-related morbidity in patients with disseminated disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.